Jann N Sarkaria
Mayo Clinic · Alliance for Clinical Trials in Oncology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jann N Sarkaria as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:26 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05917145 · ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade GliomaMayo Clinic · recruiting · Glioblastoma · principal investigator
- N/ANCT03071913 · Blood Brain Barrier Differences in Patients with Brain Tumors Undergoing SurgeryMayo Clinic · completed · Central Nervous System Neoplasm, Localized Brain Neoplasm, Metastatic Malignant Neoplasm in the Brain · principal investigator
- Ph2/Ph3NCT02152982 · Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma MultiformeNational Cancer Institute (NCI) · active not recruiting · Glioblastoma, Gliosarcoma · principal investigator
- Early Ph1NCT00757549 · 3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or HypopharynxMayo Clinic · completed · Head and Neck Cancer · study chair
- Ph1/Ph2NCT00553150 · Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed GlioblastomaAlliance for Clinical Trials in Oncology · completed · Brain and Central Nervous System Tumors · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Advanced Clinical Trials and Translational SciencesP30CA015083 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2009 to 2026 · $209,499 awarded in 2026Grant number is on one of their registry trials
- Antibody Drug Conjugate Designs to Enhance the Therapeutic Window for Brain TumorsR01NS144593 · NINDS · MAYO CLINIC ROCHESTER · fiscal years 2025 to 2026 · $620,652 awarded in 2026Same name and institution; not confirmed by an ID
- Maximizing the efficacy of MDM2 inhibitor therapy for MDM2-amplified glioblastomaR01CA285536 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2024 to 2026 · $1,928,364 awarded in 2026Same name and institution; not confirmed by an ID
- Administrative CoreU19CA264362 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2021 to 2025 · $295,668 awarded in 2025Same name and institution; not confirmed by an ID
- Development of the brain penetrant ATM inhibitor WSD0628 in combination with radiation for recurrent high grade gliomaR01FD007842 · FDA · MAYO CLINIC ROCHESTER · fiscal years 2023 to 2025 · $649,264 awarded in 2025Same name and institution; not confirmed by an ID
- In vivo SELEX strategies to identify potent aptamer-drug conjugates for glioblastomaR61NS128071 · NINDS · MAYO CLINIC ROCHESTER · fiscal years 2023 to 2024 · $386,233 awarded in 2024Same name and institution; not confirmed by an ID
- Pre-Clinical Novel Radiosensitizer Evaluation Program for Brain TumorsU01CA227954 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2018 to 2022 · $552,341 awarded in 2022Same name and institution; not confirmed by an ID
- MIT/Mayo Physical Sciences Center for Drug Distribution and Efficacy in Brain TumorsU54CA210180 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · fiscal years 2016 to 2020 · $1,990,625 awarded in 2020Grant number is on one of their registry trials
- The Mayo GBM Xenograft National ResourceR24NS092940 · NINDS · MAYO CLINIC ROCHESTER · fiscal years 2016 to 2019 · $294,973 awarded in 2019Same name and institution; not confirmed by an ID
- (PQD3) Mechanisms of prolonged initial disease-free survival in glioblastomaR01CA184320 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2014 to 2017 · $738,276 awarded in 2017Same name and institution; not confirmed by an ID
- Mechanisms of acquired temozolomide resistance in glioblastoma multiformeR01CA176830 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2013 to 2017 · $329,925 awarded in 2017Same name and institution; not confirmed by an ID
- Animal CoreP50CA108961 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2004 to 2015 · $392,176 awarded in 2015Grant number is on one of their registry trials
- Overcoming therapy resistance in GBMR01CA141121 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2009 to 2013 · $325,989 awarded in 2013Same name and institution; not confirmed by an ID
- Epigenetic regulation of temozolomide responsiveness in glioblastomaR01CA127716 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2008 to 2012 · $372,669 awarded in 2012Same name and institution; not confirmed by an ID
- Early prediction of response to combined modality therapy by functional imagingR21CA123909 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2007 to 2008 · $255,450 awarded in 2008Same name and institution; not confirmed by an ID
- DAILY ORAL SIROLIMUS (RAPA) AND CISPLATIN WITH CONCURRENT THORACIC RADIATIONM01RR000585 · NCRR · MAYO CLINIC ROCHESTER · fiscal years 2005 · $1,422 awarded in 2005Same name and institution; not confirmed by an ID
- FLT PET imaging for evaluating molecular therapeuticsR21CA104310 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2004 to 2005 · $165,938 awarded in 2005Same name and institution; not confirmed by an ID
- ATM KINASE AS A NOVEL TARGET FOR RADIOSENSITIZING AGENTSK08CA080829 · NCI · MAYO CLINIC ROCHESTER · fiscal years 1999 to 2003 · $125,418 awarded in 2003Same name and institution; not confirmed by an ID
- P53 INDUCTION AS A PREDICTOR OF RADIATION COMPLICATIONSF32CA069709 · NCI · MAYO CLINIC ROCHESTER · fiscal years 1996 to 1998 · $36,012 awarded in 1998Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer and Leukemia Group BU10CA031946 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Monica M Bertagnolli · fiscal years 1985 to 2013Named on NCT02152982
- Alliance for Clinical Trials in Oncology Member Site CoreU10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis · fiscal years 2014 to 2026Named on NCT02152982
Most cited trial papers
Clinical-trial papers with this author name in glioblastoma, ranked by citations from NIH iCite, fetched 2026-11-12 12:26 UTC. The ranking covers the 200 most relevant of 12 PubMed records, and a shared surname and initials can bring in a namesake. All 12 on PubMed
- 218 citationsRCR 4.8
- A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.Neuro Oncol · 2015136 citationsRCR 4.2
- Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.Neuro Oncol · 2018116 citationsRCR 4.0
- Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy.J Natl Cancer Inst · 201894 citationsRCR 3.2
- North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme.Int J Radiat Oncol Biol Phys · 201169 citationsRCR 1.7
- Molecular profiling of long-term IDH-wildtype glioblastoma survivors.Neuro Oncol · 201961 citationsRCR 2.7
- Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks.Clin Cancer Res · 201059 citationsRCR 1.4
- 53 citationsRCR 2.0
- Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial.JAMA Oncol · 202434 citationsRCR 3.6
- Magnetic Resonance Imaging of Iron Metabolism with T2* Mapping Predicts an Enhanced Clinical Response to Pharmacologic Ascorbate in Patients with GBM.Clin Cancer Res · 202430 citationsRCR 4.3